ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,594.63
(
0.59%
)
US Tech 100
15,629.20
(
0.49%
)
Dow Jones
36,245.50
(
0.82%
)
Brent Oil
79.125
(
0.0%
)
Bitcoin
38,797.28
(
0.24%
)
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) News

CYTO Altamira Therapeutics Ltd

0.3248
-0.0664 (-16.97%)
Dec 02 2023 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Altamira Therapeutics Ltd CYTO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
-0.0664 -16.97% 0.3248 00:00:06
Open Price Low Price High Price Close Price Prev Close
0.4236 0.301 0.46 0.319 0.3912
more quote information »

Recent News

Date Time Source Heading
11/29/202310:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
11/22/202316:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/21/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/17/202309:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
11/10/202308:47GLOBEAltamira Therapeutics Announces European Patent Office..
10/31/202316:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/04/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/14/202308:47GLOBEAltamira Therapeutics Reports Additional Significant..
9/12/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/12/202307:30GLOBEAltamira Therapeutics Provides Business Update and First..
9/06/202308:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
8/23/202308:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
8/21/202307:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
7/28/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/26/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/20/202308:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
7/17/202308:47GLOBEAltamira Therapeutics Announces Publication of Positive..
7/11/202308:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/07/202316:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
7/06/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
7/05/202308:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
6/30/202306:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
3/22/202308:47GLOBEAltamira Therapeutics’ SemaPhore Delivery Platform Shows..
2/27/202308:47GLOBEAltamira Therapeutics Files Provisional Patent Application..
1/27/202308:47GLOBEAltamira Therapeutics Provides Business Update
1/24/202308:17GLOBEAltamira Therapeutics Provides Update on Clinical Trials..
1/10/202308:47GLOBEAltamira Therapeutics to Present at 2nd Annual mRNA-Based..
12/19/202208:47GLOBEAltamira Therapeutics Provides Year-End 2022 Business Update

Your Recent History

NASDAQ
CYTO
Altamira Therapeutics
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com